Submassive pulmonary embolism

JAMA

Volumn 309, Issue 2, 2013, Pages 171-180

  Piazza, Gregory ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ATENOLOL; ENOXAPARIN; HEPARIN; HYDROCHLOROTHIAZIDE; SAXAGLIPTIN; TENECTEPLASE;

ADULT; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLOOD PRESSURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMBOLECTOMY; EMERGENCY WARD; FEMALE; FIBRINOLYSIS; HEART CYCLE; HEART RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOKINESIA; LIFESTYLE MODIFICATION; LUNG EMBOLISM; LUNG HEMODYNAMICS; MECHANICAL THROMBECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN SATURATION; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PULMONARY ARTERY; SUBMASSIVE PULMONARY EMBOLISM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VENA CAVA FILTER;

EID: 84872071625     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.164493     Document Type: Article

References (63)

1. US Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008. http: //www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt- 2008.pdf. Accessed April 10, 2012.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386-1389.
3. Jaff MR, McMurtry MS, Archer SL, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788- 1830.
4. Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation. 2010;122(11):1124-1129.
5. Piazza G, Goldhaber SZ. Fibrinolysis for acute pulmonary embolism. Vasc Med. 2010;15(5):419-428.
6. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e419S- e494S.
7. Stein PD, Matta F, Janjua M, Yaekoub AY, Jaweesh F, Alrifai A. Outcome in stable patients with acute pulmonary embolism who had right ventricular enlargement and/or elevated levels of troponin I. Am J Cardiol. 2010;106(4):558-563.
8. Stein PD, Matta F, Yaekoub AY, et al. Reconstructed 4-chamber views compared with axial imaging for assessment of right ventricular enlargement on CT pulmonary angiograms. J Thromb Thrombolysis. 2009;28(3):342-347.
9. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004;110(20):3276-3280.
10. van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235(3):798-803.
11. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med. 2005;165(15):1777- 1781.
12. Torbicki A, Perrier A, Konstantinides S, et al; ESC Committee for Practice Guidelines. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276-2315.
13. Fanikos J, Rao A, Seger AC, Piazza G, Goldhaber SZ. Hospital costs of acute pulmonary embolism. J Am Coll Cardiol. 2012;59:A519.
14. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.
15. Sharifi M. Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT). 2012. http://www.theheart.org/article/1377765.do. Accessed October 15, 2012.
16. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009;20(11):1431-1440.
17. Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005;129(5):1018-1023.
18. Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation. 2002;105(12):1416-1419.
19. Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338(7):409-415.
20. Becattini C, Agnelli G, Salvi A, et al; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3):e82-e86.
21. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase vs heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507-511.
22. Nass N, McConnell MV, Goldhaber SZ, Chyu S, Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol. 1999;83(5):804-806, A10.
23. Sharma GV, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med. 1980;303(15):842-845.
24. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest. 2009;136(5):1202-1210.
25. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364(4):351-360.
26. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med. 2000;5(2):91-95.
27. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006;97(1):127-129.
28. Chauhan MS, Kawamura A. Percutaneous rheolytic thrombectomy for large pulmonary embolism: a promising treatment option. Catheter Cardiovasc Interv. 2007;70(1):121-128.
29. Goldhaber SZ. Percutaneous mechanical thrombectomy for acute pulmonary embolism: a double-edged sword. Chest. 2007;132(2):363-365.
30. Goldhaber SZ. Percutaneous mechanical thrombectomy for massive pulmonary embolism: improve safety and efficacy by sharing information. Catheter Cardiovasc Interv. 2007;70(6):807-808.
31. Kucher N. Catheter embolectomy for acute pulmonary embolism. Chest. 2007;132(2):657-663.
32. Kucher N, Windecker S, Banz Y, et al. Percutaneous catheter thrombectomy device for acute pulmonary embolism: in vitro and in vivo testing. Radiology. 2005;236(3):852-858.
33. Mismetti P, Rivron-Guillot K, Quenet S, et al. A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest. 2007;131(1):223-229.
34. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337(10):657-662.
35. Simonneau G, Sors H, Charbonnier B, et al; THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337(10):663-669.
36. Büller HR, Davidson BL, Decousus H, et al; MATISSE Investigators. Subcutaneous fondaparinux vs intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-1702.
37. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin vs Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer Investigators. Low-molecular-weight heparin vs a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
38. Büller HR, Prins MH, Lensin AW, et al; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
39. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran vs warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
40. Schulman S, Kakkar AK, Schellong S, et al. A randomized controlled trial of dabigatran vs warfarin in the treatment of acute venous thromboembolism (RECOVER II). Presented at: American Society of Hematology Annual Meeting; December 12, 2011; San Diego, CA. Abstract 205.
41. Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. Circulation. 2011;123(6):664-667.
42. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
43. Kearon C, Ginsberg JS, Kovacs MJ, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631-639.
44. Ridker PM, Goldhaber SZ, Danielson E, et al; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-1434.
45. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-1721.
46. Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-1967.
47. Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979-1987.
48. Schulman S, Baanstra D, Eriksson H, et al. Dabigatran vs placebo for extended maintenance therapy of venous thromboembolism. Presented at: International Society on Thrombosis and Haemostasis 2011; July 25, 2011; Kyoto, Japan. Abstract O-MO-037.
49. Schulman S, Eriksson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Presented at: International Society on Thrombosis and Haemostasis 2011; July 28, 2011; Kyoto, Japan. Abstract O-TH-033.
50. Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of hospitalization for venous thromboembolism. Circulation. 2012;125(17):2092-2099.
51. Bauer KA. Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism. JAMA. 2011;305(13):1336-1345.
52. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117(1):93-102.
53. Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V; Million Women Study Collaborators. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation. 2012;125(15):1897-1904.
54. Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation. 2010;121(19):2146-2150.
55. Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost. 2011;106(6):1095-1102.
56. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435-1441.
57. Spencer FA, Ginsberg JS, Chong A, Alter DA. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost. 2008;6(9):1507-1513.
58. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370(9601):1773-1779.
59. Goldhaber SZ, Morrison RB. Pulmonary embolism and deep vein thrombosis. Circulation. 2002;106(12):1436-1438.
60. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523-1532.
61. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e120S-e151S.
62. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997;80(2):184-188.
63. Parker JA, Drum DE, Feldstein ML, Goldhaber SZ. Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med. 1995;36(3):364-368.